Ang1-Expressing Stem Cells for Diabetes Without Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diabetes, such as regular insulin injections, fail to maintain smooth blood glucose levels, leading to complications like hyperglycemia and hypoglycemia, and stem cell-based treatments face challenges with autoimmune issues requiring lifelong immunosuppression.
Innovation Solution
Administering genetically unmodified stem cells that express high levels of Angiopoietin-1 (Ang1) to increase anti-inflammatory cells, reducing TNF-alpha, IL-6, and increasing IL-10 levels, thereby treating inflammatory disorders like diabetes and associated conditions without the need for transfection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If stem cell-based technologies are used to treat diabetes, then new treatment options are provided, but issues related to autoimmune disease require lifelong immunosuppression
Solution Approach 1:
The patent uses Ang1 as an intermediary molecule to mediate the interaction between stem cells and the immune system. Ang1-expressing stem cells act as mediators that modulate immune responses without requiring systemic immunosuppression, thereby providing a targeted therapeutic approach that avoids the complexity of lifelong immunosuppressive therapy
2Duration of action of moving object
If delayed-action insulin preparations are administered to achieve constant basal level, then sustained action is achieved, but smooth background levels are not produced resulting in hyperglycemia or hypoglycaemia
Solution Approach 1:
The patent changes the therapeutic parameter from direct insulin administration to Ang1-mediated immune modulation. By altering the mechanism of action from hormone replacement to anti-inflammatory therapy, the treatment achieves more stable metabolic control without the oscillations in blood glucose levels that characterize delayed-action insulin preparations
Data Source
AI summary
The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.